Vyera and Martin Shkreli fail in bid to end Daraprim lawsuit
Defendant Martin Shkreli testifying before Congress in 2016; Wikipedia Commons/House Committee on Oversight and Government Reform
A federal judge in New York has ruled that Martin Shkreli and his company Vyera Pharmaceuticals must face an FTC lawsuit accusing them of scheming to maintain the company’s monopoly over antiparasitic drug Daraprim.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10